According to Woofun AI, Thermo Fisher Scientific (TMO.US) is scheduled to disclose the third quarter earnings report on October 21. The top Wall Street analysts have raised profit expectations previously, and the market focus has turned to delivering results. This adjustment reflects the organization's increased confidence in the company's continued profitability in the field of scientific instruments and diagnostics.

The financial consensus is expected to show a steady growth trend. Thermo Fisher Scientific (TMO.US), headquartered in Waltham, Massachusetts, is listed on the New York Stock Exchange. Analysts expect earnings per share to reach $6.40, up from $5.79 in the same period last year. In terms of revenue, the consensus forecast was $11.93 billion.

According to data compiled by Woofun AI, compared to last year's revenue base of $11.12 billion, this growth trajectory shows a clear expansion logic.

Business synergy has recently become the focus of the market. On October 6, Quantum Biopharmaceuticals Co., Ltd. (QNTM.US) announced a partnership with Thermo Fisher Scientific (TMO.US) clinical research department to jointly advance phase II clinical trials of Lucid-MS drugs for the treatment of multiple sclerosis. Affected by multiple factors, TMO's stock price fell 1.5% to close at $679.38 on Monday, and the market made short-term valuation adjustments while digesting news of the cooperation.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.